// App-Quantinova.ai

DMT23 : Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Researchers

Presenter

  • Dean Wingerchuk

Principal Investigators

  • Achim Berthele

  • Kazuo Fujihara

  • Celia Oreja-Guevara

  • Ho Jin Kim

  • Michael Levy

  • Ichiro Nakashima

  • Jacqueline Palace

  • Shulian Shang

  • Marcus Yountz

  • Larisa Miller

  • Sean J Pittock

Medical Centers

  • Hospital Universitario Clinico San Carlos, Madrid, Spain

  • Mayo Clinic, Rochester, MN

  • Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan, Tohoku University, Sendai, Japan, Fukushima Medical University, Fukushima City, Japan

  • Research Institute and Hospital of National Cancer Center, Goyang, KOREA, REPUBLIC OF

  • Mayo Clinic, Scottsdale, AZ

  • Alexion Pharmaceuticals, Boston, MA

  • Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany

  • Massachusetts General Hospital and Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD

  • Tohoku Medical and Pharmaceutical University, Sendai, Japan, Tohoku University, Sendai, Japan

  • John Radcliffe Hospital, Oxford, United Kingdom.

Locations

  • Spain

  • United States

  • Germany

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Central Nervous System (CNS)

Disease

  • Neuromyelitis optica

Biomarkers

  • N/A

Drug/Treatment

  • Eculizumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • NCT01892345

  • NCT02003144

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved